Epilepsy Research
Volume 29, Issue 2 , Pages 109-114 , January 1998

Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients

  • Mårten Kyllerman

      Affiliations

    • Departments of Pediatrics, Sahlgren University Hospital, 413 45 Göteborg, Sweden
    • ,
  • Elinor Ben-Menachem

      Affiliations

    • Department of Neuroscience, Neurology Division, Sahlgren University Hospital, 413 45 Göteborg, Sweden
    • Corresponding Author InformationCorresponding author.

Received 7 April 1997 ,Revised 27 July 1997 ,Accepted 3 August 1997.

References 

  1. Berkovic SF, Cochius J, Andermann E, Andermann F. Progressive myoclonus epilepsies: Clinical and genetic aspects. Epilepsia. 1993;34(suppl 3):S19–30
  2. Yamakawa K, Mitchell S, Hubert R, Chen X-N, Colbern S, Huo Y-K, et al.  Isolation and characterization of a candidate gene for progressive myoclonus epilepsy on 21q22.3. Hum Mol Genet. 1995;4:709–716
  3. Serratosa JM, Delgado-Escueta A, Posada I, Shih S, Drury I, Berciano J, et al. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosone 6q. Hum Mol Genet. 1995;4:1657–1663
  4. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonusepilepsy. Acta Neurol. 1982;39:236–238
  5. Henry TR, Leppik IE, Gummit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology. 1982;38:928–931
  6. Kyllerman M, Sommerfeldt K, Hedström A, Wennergren G, Holmgren D. Clinical and neurophysiological development of Univerricht-Lundborg Disease in four Swedish siblings. Epilepsia. 1991;32:900–909
  7. Lundborg H. Klinische studier und erfahrungen hinsichtlich der familiaren myoklonie und damn' verwandter krankheiten. Stockholm: Issac Marcus Boktr-Aktiebolag, 1901.
  8. Lehesioki AK, Koskiniemi M, Pandolfo M, Antonielli A, Kyllerman M, et al.  Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora's disease. Neurology. 1992;42:1545–1550
  9. Oguni H, Hayashi K, Fukuyama Y, et al. Phase III study of a new antiepileptic AD-810, zonisamide in childhood epilepsy. Jap J Pediatr (in Japanese) 41;1988:439–450.
  10. Pennacchio LA, Lehesjoki AK, Stone NE, Willour VL, Virtaneva K, Miao J, et al.  Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy. Science. 1996;217:1731–1734
  11. Seino M, Okuma T, Miyazaka M, et al. Efficacy evaluation of AD-810 (zonisamide). Double-blind study comparing with carbamazepine. J Clin Exp Med. 1988;144:275–291 (in Japanese).
  12. Seino M, Naruto S, Tsugutaka I, Miyazaki H. Other antiepileptic drugs: Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs. 4th edn. New York: Raven Press, 1995:1011–1023.
  13. Eldridge R, Iivanainen M, Stern R, Joerber T, Wilder BJ. `Baltic' myoclonic epilepsy: H hereditary disorder of childhood made worse by phenytoin. Lancet. 1983;2:838–842
  14. Schmidt D, Jacob R, Loiseau P, et al.  Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res. 1993;15:67–73
  15. Leppik IE, Willmore LJ, Homan RW, Fromm G, Oommen KJ, Penry JK, et al. Efficacy and safety of zonisamide: Results of a multicenter study. Epilepsy Res. 1993;14:165–173
  16. Wilder BJ, Ramsay RE, Guterman A, et al. A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically intractable patients. Internal report of Dainippon Pharmaceutical, 1986.

PII: S0920-1211(97)00069-7

Epilepsy Research
Volume 29, Issue 2 , Pages 109-114 , January 1998

Article Tools